APOE and Alzheimer disease: Although in the short-term, partial reduction of liver Apoe by di-siRNA does not translate into detectable serum cholesterol changes in wild-type or AD mouse models (36) and can be controlled by dose reduction, long-term partial reduction may have a more significant impact.